These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 20571535)
21. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists. López JM; Oestreicher E Fertil Steril; 2005 Sep; 84(3):756. PubMed ID: 16169415 [TBL] [Abstract][Full Text] [Related]
22. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Pereira AM Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709 [TBL] [Abstract][Full Text] [Related]
23. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Senol MG; Togrol RE Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893 [No Abstract] [Full Text] [Related]
24. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Ioachimescu AG; Fleseriu M; Hoffman AR; Vaughan Iii TB; Katznelson L Eur J Endocrinol; 2019 Jan; 180(1):31-40. PubMed ID: 30400048 [TBL] [Abstract][Full Text] [Related]
26. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Kilicdag EB; Tarim E; Bagis T; Erkanli S; Aslan E; Ozsahin K; Kuscu E Int J Gynaecol Obstet; 2004 Jun; 85(3):292-3. PubMed ID: 15145274 [No Abstract] [Full Text] [Related]
27. Cabergoline and mitral regurgitation. Delgrange E N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779 [No Abstract] [Full Text] [Related]
28. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia. Miki N Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939 [No Abstract] [Full Text] [Related]
29. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. Kars M; Souverein PC; Herings RM; Romijn JA; Vandenbroucke JP; de Boer A; Dekkers OM J Clin Endocrinol Metab; 2009 Aug; 94(8):2729-34. PubMed ID: 19491225 [TBL] [Abstract][Full Text] [Related]
30. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478 [TBL] [Abstract][Full Text] [Related]
31. Dopamine agonist therapy and cardiac valve dysfunction. Sherlock M; Steeds R; Toogood AA Clin Endocrinol (Oxf); 2007 Nov; 67(5):643-4. PubMed ID: 17645575 [No Abstract] [Full Text] [Related]
32. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978 [TBL] [Abstract][Full Text] [Related]
33. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688 [TBL] [Abstract][Full Text] [Related]